Publications & Works

Publication Network
Articles 28
All (28)
SCI-E, SSCI, AHCI (25)
SCI-E, SSCI, AHCI, ESCI (27)
ESCI (2)
Scopus (26)
TRDizin (2)

1. Stressful life events, psychiatric comorbidities and serum neuromediator levels in patients with chronic spontaneous urticaria treated with omalizumab

Akdaş E., GÜLEKON A., Bulut T. S. D., GÜLBAHAR Ö., Öztürk M., BAŞARAN A. S., et al.
Allergologia et Immunopathologia , vol.52, no.3, pp.1-7, 2024 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

2. The correlation analysis between alterations of serum vitamin D, IL-33 levels, and clinical improvement after narrow-band UVB treatment in vitiligo patients: A case-control study

Soyer E., Temel B., BUKAN N., YILMAZ C., GÜLEKON A.
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE , vol.40, no.1, 2024 (SCI-Expanded, Scopus) Sustainable Development identifier identifier identifier

3. Should Cervical Cancer Screening with Papanicolaou Smear be Recommended for Female Patients with Psoriasis before Biological Agent Treatment?

Tamer F., Özdemir İ., Gülekon A.
ROMANIAN JOURNAL OF MILITARY MEDICINE , vol.126, no.4, pp.457-461, 2023 (ESCI) identifier

4. MONOCYTE TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL RATIO DECREASED IN PATIENTS WITH PSORIASIS TREATED WITH IXEKIZUMAB

Tamer F., Kucukhemek F., Gulekon A.
REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION , vol.75, no.4, pp.187-192, 2023 (SCI-Expanded, Scopus) Sustainable Development identifier identifier identifier

5. Characteristics of pruritus in various clinical variants of psoriasis: Final report of the binational, multicentre, cross-sectional study

Jaworecka K., Kwiatkowska D., Marek-Jozefowicz L., Tamer F., Stefaniak A., Szczegielniak M., et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY , vol.37, no.4, pp.787-795, 2023 (SCI-Expanded, Scopus) Sustainable Development identifier identifier identifier

6. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience

AKDAŞ E., ADIŞEN E., ÖZTAŞ M. O., AKSAKAL A. B., İLTER N., GÜLEKON A.
Anais Brasileiros de Dermatologia , vol.98, no.2, pp.240-242, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

7. The Impact of Pruritus on the Quality of Life and Sleep Disturbances in Patients Suffering from Different Clinical Variants of Psoriasis

Jaworecka K., Rzepko M., Marek-Jozefowicz L., Tamer F., Stefaniak A. A., Szczegielniak M., et al.
JOURNAL OF CLINICAL MEDICINE , vol.11, no.19, 2022 (SCI-Expanded, Scopus) Creative Commons License Sustainable Development identifier identifier identifier

8. Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center.

Afacan E., Edek Y. C., İlter N., Gülekon A.
International journal of dermatology , vol.61, pp.626-627, 2022 (SCI-Expanded, Scopus) Sustainable Development identifier identifier identifier

9. Should Mammography Be a Prerequisite Prior to Initiation of Biological Agents in Patients With Psoriasis?

Tamer F., Gülekon A.
DERMATOLOGY PRACTICAL & CONCEPTUAL , vol.12, no.2, 2022 (SCI-Expanded, Scopus) Creative Commons License Sustainable Development identifier identifier identifier

10. Clinical characteristics, quality of life and risk factors for severity in palmoplantar pustulosis: a cross-sectional, multicentre study of 263 patients

SOLAK S. S., Polat A. K., Kilic S., Topal I. O., Saricaoglu H., Karadag A. S., et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY , vol.47, no.1, pp.63-71, 2022 (SCI-Expanded) Sustainable Development identifier identifier identifier

11. Tuberculosis screening guidelines should be updated and quantiferon test should be a prerequisite prior to the initiation of treatment of psoriasis with biological agents

Tamer F., Gülekon A.
European Review for Medical and Pharmacological Sciences , vol.26, no.23, pp.8788-8794, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

12. Characteristics of Pruritus in Various Clinical Variants of Psoriasis: Results of the Multinational, Multicenter, Cross-Sectional Study

Jaworecka K., Kwiatkowska D., Marek L., Tamer F., Stefaniak A., Szczegielniak M., et al.
LIFE-BASEL , vol.11, no.7, 2021 (SCI-Expanded, Scopus) Sustainable Development identifier identifier identifier

13. Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene

Tamer F., Gülekon A.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN , vol.31, no.6, pp.716-718, 2021 (SCI-Expanded, Scopus) Sustainable Development identifier identifier identifier

14. Evaluation of perilipin 2 and melanocortin 5 receptor serum levels with sebogenesis in acne vulgaris patients

Orenay O. M., Sarifakioglu E., GÜLEKON A.
ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA , vol.30, no.1, pp.7-9, 2021 (ESCI, Scopus) identifier identifier identifier

15. Internalized stigma in pediatric psoriasis: A comparative multicenter study

ALPSOY E., Polat M., Yavuz İ. H., Kartal P., Balci D. D., Karadag A. S., et al.
Annals of Dermatology , vol.32, no.3, pp.181-188, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

16. The relationship of osteopontin and related cytokin levels with disease activity, treatment and comorbidities in psoriasis vulgaris

Bulur I., GÜLEKON A., ERDEM O. A., Yucel A., Celik S., Aral A.
TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY , vol.47, no.3, pp.142-147, 2013 (SCI-Expanded) identifier identifier

17. Therelationshipofosteopontin and related cytokin levels with disease activity, treatment and comorbidities in psoriasis vulgaris

BULUR I., GÜLEKON A., ERDEM Ö., ÇELİK S., YÜCEL A. A., ARAL L. A.
Türkderm-Deri Hastalıkları ve Frengi Arşivi , vol.47, no.3, pp.142-147, 2013 (SCI-Expanded, TRDizin) identifier

18. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients

Adisen E., Tekin O., Guelekon A., Guerer M. A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY , vol.23, no.7, pp.814-819, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

19. Psoriasis and Co-morbidities

GÜLEKON A., ADIŞEN E.
TURKDERM-ARCHIVES OF THE TURKISH DERMATOLOGY AND VENEROLOGY , vol.42, pp.23-25, 2008 (SCI-Expanded, Scopus, TRDizin) identifier identifier

20. Changes in serum carbonyl and malondialdehyde levels following colchicine and vitamin E treatment in Behcet's disease

Gulbahar Ö., Adisen H., Koca C., Aricioglu A., Gulekon A.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY , no.8, pp.521-524, 2007 (SCI-Expanded) Sustainable Development identifier identifier identifier

21. The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis

Adisen E., Gulekon A., ERDEM O. A., Dursun A., Gurer M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY , vol.20, no.5, pp.527-533, 2006 (SCI-Expanded, Scopus) identifier identifier identifier

22. Hypopigmented mycosis fungoides in an adolescent Turkish boy

Gulekon A., Ozsoy E., Gurer M., Ataoglu O.
INTERNATIONAL JOURNAL OF DERMATOLOGY , vol.44, no.9, pp.795-796, 2005 (SCI-Expanded, Scopus) identifier identifier identifier

23. Natural killer cell activity, serum immunoglobulins, complement proteins, and zinc levels in patients with psoriasis vulgaris

Ozturk G., Erbas D., Gelir E., Gulekon A., Imir T.
IMMUNOLOGICAL INVESTIGATIONS , vol.30, no.3, pp.181-190, 2001 (SCI-Expanded, Scopus) identifier identifier identifier

24. HLA DR, DQA, DQB and DP antigens in patients allergic to nickel

Onder M., Aksakal B., Gulekon A., Makki S., Gurer M., Barut A.
CONTACT DERMATITIS , vol.33, no.6, pp.434-435, 1995 (SCI-Expanded, Scopus) identifier identifier identifier

25. Natural cellular cytotoxicity in Behcet's disease

ÖNDER M., Bozkurt M., GÜRER M., GÜLEKON A., Sezgin P., İMİR T.
Journal of Dermatology , vol.21, no.4, pp.239-243, 1994 (Scopus) identifier identifier

26. ARACHIDONIC-ACID METABOLITES AND COLCHICINE IN BEHCETS-DISEASE (BD)

GURER M., KESKIN N., GULEKON A., KAREL L., AKSAKAL B., BAYSAL V.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS , vol.43, no.4, pp.257-259, 1991 (SCI-Expanded, Scopus) identifier identifier identifier identifier

27. THE EFFECTS OF DNCB THERAPY ON THE T-CELL SUBSETS OF THE CASES WITH ALOPECIA-AREATA

GULEKON A., GURER M., BOZKURT M., KESKIN N.
INTERNATIONAL JOURNAL OF DERMATOLOGY , vol.28, no.10, pp.684-685, 1989 (SCI-Expanded, Scopus) Sustainable Development identifier identifier identifier

28. ARACHIDONIC-ACID METABOLITES IN BEHCETS-DISEASE

BOZKURT M., GURER M., GULEKON A., KESKIN N., ERCAN S.
INTERNATIONAL JOURNAL OF DERMATOLOGY , vol.28, no.2, pp.141-142, 1989 (SCI-Expanded, Scopus) Sustainable Development identifier identifier identifier
Papers Presented at Peer-Reviewed Scientific Conferences 2

1. Edinsel Perforan Dermatoz Tanısı Olan 75 Hastanın Klinik ve Histopatolojik Özelliklerinin Retrospektif İncelenmesi: Tek Merkez Deneyimi

EDEK Y. C., AYPEK Y., ADIŞEN E., ÖĞÜT B., ÖZTAŞ M. O., AKSAKAL A. B., et al.
30. Ulusal Dermatoloji Kongresi, Cyprus (Kktc), 19 October 2022, (Summary Text)

2. Sweet Sendromu Tanılı 25 Hastanın Retrospektif Analizi: Tek Merkez Deneyimi

EDEK Y. C., ADIŞEN E., ÖĞÜT B., ÖZTAŞ M. O., AKSAKAL A. B., İLTER N., et al.
30. Ulusal Dermatoloji Kongresi, Cyprus (Kktc), 19 October 2022, (Summary Text)
Metrics

Publication

31

Publication (WoS)

27

Publication (Scopus)

26

Citation (WoS)

219

H-Index (WoS)

9

Citation (Scopus)

271

H-Index (Scopus)

9

Citation (TrDizin)

4

H-Index (TrDizin)

1

Citation (Sum Other)

8

Project

5

Thesis Advisory

10

Open Access

6
UN Sustainable Development Goals